Volume 130, Issue 1, Pages (January 2006)

Slides:

Advertisements

Similar presentations

Celiac disease–like abnormalities in a subgroup of patients with irritable bowel syndrome Ulrich Wahnschaffe, R. Ullrich, E.O. Riecken, J.D. Schulzke Gastroenterology.

Advertisements

Overview and pathogenesis of celiac disease Martin F. Kagnoff Gastroenterology Volume 128, Issue 4, Pages S10-S18 (April 2005) DOI: /j.gastro

Volume 129, Issue 1, Pages (July 2005)

A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome

Some Patients With Irritable Bowel Syndrome May Have Exocrine Pancreatic Insufficiency John S. Leeds, Andrew D. Hopper, Reena Sidhu, Alison Simmonette,

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS Simon P Dunlop, David Jenkins, Keith R Neal,

Volume 145, Issue 4, Pages (October 2013)

Volume 130, Issue 1, Pages (January 2006)

Volume 134, Issue 7, Pages (June 2008)

Prevalence, Characteristics, and Impact of Bloating Symptoms in Patients With Irritable Bowel Syndrome Yehuda Ringel, Rachel E. Williams, Linda Kalilani,

Volume 128, Issue 3, Pages (March 2005)

Relaxation Therapy for Irritable Bowel Syndrome: A Systematic Review

Volume 129, Issue 5, Pages (November 2005)

Charles D. Gerson, Mary-Joan Gerson

Brian Bond, Judith Quinlan, George E. Dukes, Fermin Mearin, Ray E

Diagnosis of irritable bowel syndrome

Christoph Lübbert, Babett Holler Gastroenterology

Diagnosis of celiac sprue

Covering the Cover Gastroenterology

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS Simon P Dunlop, David Jenkins, Keith R Neal,

Simon P. Dunlop, Nicholas S. Coleman, Elaine Blackshaw, Alan C

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? William E. Whitehead, Olafur.

Volume 154, Issue 3, Pages e2 (February 2018)

Covering the Cover Gastroenterology

Volume 133, Issue 5, Pages (November 2007)

The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders Michael D. Gershon, Jan Tack Gastroenterology

Novel Evidence for Hypersensitivity of Visceral Sensory Neural Circuitry in Irritable Bowel Syndrome Patients Adeyemi Lawal, Mark Kern, Harjot Sidhu,

Volume 132, Issue 1, Pages (January 2007)

Ira J. Fox, Stephen C. Strom Gastroenterology

American Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease Peter J. Kahrilas, Nicholas.

Volume 141, Issue 5, Pages (November 2011)

A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome

Volume 130, Issue 5, Pages (April 2006)

Volume 154, Issue 5, Pages (April 2018)

Volume 145, Issue 2, Pages e1 (August 2013)

Volume 133, Issue 3, Pages e1 (September 2007)

Volume 150, Issue 4, Pages (April 2016)

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Partner Burden in Irritable Bowel Syndrome

Volume 149, Issue 2, Pages (August 2015)

Volume 141, Issue 2, Pages (August 2011)

Volume 151, Issue 6, Pages (December 2016)

Volume 131, Issue 2, Pages (August 2006)

A Comprehensive Self-Management Irritable Bowel Syndrome Program Produces Sustainable Changes in Behavior After 1 Year Jasmine K. Zia, Pamela Barney,

Severe Constipation Clinical Gastroenterology and Hepatology

Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic.

Functional Bowel Disorders

2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome Lin Chang, Margaret M. Heitkemper,

Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis Elizabeth J. Videlock, Vivian.

Volume 130, Issue 1, Pages (January 2006)

Volume 153, Issue 4, Pages (October 2017)

Bowel Urgency in Patients With Irritable Bowel Syndrome

Covering the Cover Gastroenterology

Some Patients With Irritable Bowel Syndrome May Have Exocrine Pancreatic Insufficiency John S. Leeds, Andrew D. Hopper, Reena Sidhu, Alison Simmonette,

Volume 134, Issue 7, Pages (June 2008)

Effects of Different Coping Strategies on Physical and Mental Health of Patients With Irritable Bowel Syndrome Lilian Dindo, PhD Clinical Gastroenterology.

The Rise and Fall (and Rise?) of Endoscopic Anti-Reflux Procedures

Pathophysiology and treatment of functional dyspepsia

Covering the Cover Gastroenterology

Chronic Diarrhea Clinical Gastroenterology and Hepatology

Severe irritable bowel and functional abdominal pain syndromes: Managing the patient and health care costs George F. Longstreth, Douglas A. Drossman

Michelle Maria Pietzak Gastroenterology

Choosing outcome variables: global assessment and diaries

Quantitative Meta-analysis Identifies Brain Regions Activated During Rectal Distension in Irritable Bowel Syndrome Kirsten Tillisch, Emeran A. Mayer,

Volume 133, Issue 4, Pages (October 2007)

Volume 139, Issue 1, Pages (July 2010)

Bowel Urgency in Patients With Irritable Bowel Syndrome

Covering the Cover Gastroenterology

Covering the Cover Gastroenterology

Clinical Case: Chronic Constipation

Presentation transcript:

Volume 130, Issue 1, Pages 34-43 (January 2006) Altered 5-Hydroxytryptamine Signaling in Patients With Constipation- and Diarrhea- Predominant Irritable Bowel Syndrome Wendy Atkinson, Stephen Lockhart, Peter J. Whorwell, Brian Keevil, Lesley A. Houghton Gastroenterology Volume 130, Issue 1, Pages 34-43 (January 2006) DOI: 10.1053/j.gastro.2005.09.031 Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 1 Profile of overall symptom score with respect to meal ingestion (t = 0) in patients with constipation (■)- and diarrhea (•)-predominant IBS and in healthy controls (▵). Data are mean and 95% confidence interval. Gastroenterology 2006 130, 34-43DOI: (10.1053/j.gastro.2005.09.031) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 2 Profiles of 5-hydroxytryptamine (5-HT) (A) and 5-hydroxyindoleacetic acid (5-HIAA) (B) concentrations and ratio of 5-HIAA:5-HT (C) with respect to meal ingestion (t = 0) in patients with constipation (■)- and diarrhea (•)-predominant IBS and healthy controls (▵). Data are geometric mean and 95% confidence interval. Gastroenterology 2006 130, 34-43DOI: (10.1053/j.gastro.2005.09.031) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 3 Typical profiles of 5-hydroxytryptamine (5-HT) (A) and 5-hydroxyindoleacetic acid (5-HIAA) (B) concentrations in individual patients with constipation (■)- and diarrhea (•)-predominant IBS and healthy controls (▵). The dashed line represents a profile seen in an individual who exhibited repeated sharp rises and falls in plasma 5-HT concentration with time. The latter pattern of 5-HT profile was seen in 38% of c-IBS, 11% of d-IBS, and 14% of HV (overall difference, P = .008). Gastroenterology 2006 130, 34-43DOI: (10.1053/j.gastro.2005.09.031) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 4 Individual plots of values for the time to peak 5-hydroxytryptamine (5-HT) concentration in patients with constipation (■)- and diarrhea (•)-predominant IBS and healthy controls (▵). Gastroenterology 2006 130, 34-43DOI: (10.1053/j.gastro.2005.09.031) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 5 Individual plots of values for platelet 5-hydroxytryptamine (5-HT) concentration in patients with constipation (■)- and diarrhea (•)-predominant IBS and healthy controls (▵). Gastroenterology 2006 130, 34-43DOI: (10.1053/j.gastro.2005.09.031) Copyright © 2006 American Gastroenterological Association Terms and Conditions